Expression Of c-erbB-2 And p53 In Colorectal Carcinoma In Egyptian Patients Before And After The Age Of 40 Years
Ragaey R. Fahmy MD, Hala A. Agina, Ph.D. And Nadia M. Mokhtar, Ph.D.
Departments of pathology, Benha faculty of medicine, Benha University and National Cancer Institute
a b s t r a c t
Clinicopathological data and the expression of oncogene c-erbB-2 and tumour suppressor gene p35 were studied by immunohistochemistry on paraffin-embedded sections of 33 cases of primary colorectal cancer in Egyptian patients.
P27 expression in non-metastasizing PTC was lower than normal thyroid tissue (P≤ 0.01) and higher than metastasizing PTC (P≤ 0.01), p53 immunoreactivity was present, faint (grade 1) in 2 cases (11%) and moderate (grade 2) in one case ( 5.5%) of non-metastasizing PTC, while 15 (83.5%) cases on non-metastasizing PTCs and all of metastasizing PTCs and normal thyroid tissue had no immunoreactivity for p53. There was no statistically significanct difference among all groups of immunoreactivity for p53. Expression of Bax in patients with PTC was more than normal thyroid tissue ( P≤ 0.01). However, non-metastasizing and metastasizing PTC was similar. The results indicate that the metastasizing PTC showed significantly low CD44 expression than the non-metastasizing PTC (p ≤ 0.05), also the metastasizing and non-metastasizing PTC showed significantly less CD44 expression than the normal tissue (p≤ 0.05).
These findings indicate more genetic instability in familial breast cancer which can be used to estimate the probability that a carrier of p53 germline mutation may develop breast cancer at a given age.
Research in J. Egypt. Soc. Pathol. 17 (1)(1998) 69–77
|
